Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Express Scripts Says Customers Support Removal Of Several Pfizer Products From Formulary

This article was originally published in The Pink Sheet Daily

Executive Summary

Decision to drop Lipitor and Norvasc from its 2006 formulary represents an opportunity for savings without compromising health outcomes, the PBM says.
Advertisement

Related Content

Express Scripts Sees Rapid Switching to Zocor
Express Scripts Sees Rapid Switching to Zocor
FDA’s Trigger Policy For Generic Lawsuit Decisions “Facilitates Certainty,” Court Rules
FDA’s Trigger Policy For Generic Lawsuit Decisions “Facilitates Certainty,” Court Rules
Express Scripts Sees Opportunity For 75% Generic Fill Rate
Express Scripts Sees Opportunity For 75% Generic Fill Rate
Part D Formulary Negotiations Take “Portfolio Approach” For AstraZeneca
Part D Formulary Negotiations Take “Portfolio Approach” For AstraZeneca
Pfizer Will Work With Express Scripts’ Customers To Provide Lipitor
Pfizer Will Work With Express Scripts’ Customers To Provide Lipitor

Topics

Advertisement
UsernamePublicRestriction

Register

PS061175

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel